A novel liposomal vaccine improves humoral immunity and prevents tumor pulmonary metastasis in mice.
Basic fibroblast growth factor (bFGF) is an important stimulator of angiogenesis involving in neovascularization progression. The aim of this study is to evaluate whether a liposomal vaccine (MLB) based on xenogeneic human bFGF plus monophosphoryl lipid A (MPLA) could effectively induce cross-reaction immunity in mice and increase antitumor activity. Sera of mice were analyzed and IgG antibody titer in MLB group was obviously higher than other groups including the mice immunized with liposomal bFGF vaccine, bFGF plus Freund's adjuvant, empty liposome and PBS. Furthermore, tumor metastasis was significantly inhibited in MLB group, compared with L and PBS group. The IFN-γ production of cultured splenocytes in vitro was evidently up-regulated meanwhile IL-4 production sustained in a low level, revealing that this vaccine stimulated Th1 immunity response preferentially. Taken together, these findings suggested that this novel bFGF vaccine could effectively induce humoral immunity through cross-reaction, mediate Th1 immune response preferentially and enhance antitumor activity in vivo.
Zhong
Zhenghua
Z
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan, China.
Wei
Xin
X
Qi
Baowen
B
Xiao
Wenjing
W
Yang
Li
L
Wei
Yuquan
Y
Chen
Lijuan
L
D000818:Animals; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000627:therapeutic use*; D018827:Carcinoma, Lewis Lung / Q000276:immunology / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control* / Q000556:secondary*; D045744:Cell Line, Tumor; D003429:Cross Reactions / Q000276:immunology; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000037:antagonists & inhibitors* / Q000276:immunology; D006801:Humans; D056724:Immunity, Humoral; D008050:Lipid A / Q000031:analogs & derivatives / Q000737:chemistry; D008081:Liposomes; D051379:Mice; D008810:Mice, Inbred C57BL; D009389:Neovascularization, Pathologic / Q000276:immunology / Q000517:prevention & control*; D011994:Recombinant Proteins / Q000276:immunology; D018417:Th1 Cells / Q000276:immunology
D019496:Cancer Vaccines; D008050:Lipid A; D008081:Liposomes; D011994:Recombinant Proteins; D016222:Fibroblast Growth Factor 2; C048436:monophosphoryl lipid A